Table 2.
Baseline Characteristics of CKD patients Aged 18 Years or Above With Type 2 Diabetes, Medicare 20% CKD claims, 2013-2018
| Baseline characteristics | Overall cohort | SGLT2i/GLP-1RA | Sulfonylurea |
|---|---|---|---|
| Total (n) | 18,567 | 2,528 | 16,039 |
| Age, y | |||
| mean (SD) | 72.9 (10.0) | 68.8 (9.9) | 73.5 (9.9) |
| Age category, y | |||
| 18-64 | 2,594 (14.0%) | 551 (21.8%) | 2,043 (12.7%) |
| 65-74 | 7,929 (42.7%) | 1,334 (52.8%) | 6,595 (41.1%) |
| 75-84 | 5,865 (31.6%) | 549 (21.7%) | 5,316 (33.1%) |
| ≥85 | 2,179 (11.7%) | 94 (3.7%) | 2,085 (13.0%) |
| Sex | |||
| Male | 9,262 (49.9%) | 1,223 (48.4%) | 8,039 (50.1%) |
| Female | 9,305 (50.1%) | 1,305 (51.6%) | 8,000 (49.9%) |
| Race/Ethnicity | |||
| White | 14,598 (78.6%) | 2,069 (81.8%) | 12,529 (78.1%) |
| Black | 2,396 (12.9%) | 244 (9.7%) | 2,152 (13.4%) |
| Other/unknown | 1,573 (8.5%) | 215 (8.5%) | 1,358 (8.5%) |
| Low-income subsidy (LIS) status | |||
| Non-LIS | 12,384 (66.7%) | 1,721 (68.1%) | 10,663 (66.5%) |
| LIS | 6,183 (33.3%) | 807 (31.9%) | 5,376 (33.5%) |
| CKD stage | |||
| 1/2 | 1,832 (9.9%) | 312 (12.3%) | 1,520 (9.5%) |
| 3 | 6,474 (34.9%) | 697 (27.6%) | 5,777 (36.0%) |
| 4/5 | 738 (4.0%) | 37 (1.5%) | 701 (4.4%) |
| Unk/Unspc | 9,523 (51.3%) | 1,482 (58.6%) | 8,041 (50.1%) |
| Metformin | 11,241 (60.5%) | 1,691 (66.9%) | 9,550 (59.5%) |
| Nonglucose-lowering medications associated with hyperglycemia | 11,164 (60.1%) | 1,599 (63.3%) | 9,565 (59.6%) |
| Statins | 9,862 (53.1%) | 1,424 (56.3%) | 8,438 (52.6%) |
| Tricyclic antidepressants | 659 (3.5%) | 137 (5.4%) | 522 (3.3%) |
| Corticosteroids | 2,246 (12.1%) | 287 (11.4%) | 1,959 (12.2%) |
| Nonglucose-lowering medications associated with hypoglycemia | 4,884 (26.3%) | 743 (29.4%) | 4,141 (25.8%) |
| Antibiotics | 1,890 (10.2%) | 248 (9.8%) | 1,642 (10.2%) |
| SSRIs | 3,094 (16.7%) | 514 (20.3%) | 2,580 (16.1%) |
| MAOIs | ∗ | ∗ | ∗ |
| Antihypertensives (noncardioselective) | 431 (2.3%) | 56 (2.2%) | 375 (2.3%) |
| Elixhauser comorbidity index score | |||
| mean (SD) | 8.5 (8.9) | 6.1 (8.0) | 8.8 (9.0) |
Note: ∗refers to counts of 10 or fewer patients.
Abbreviations: CKD, chronic kidney disease; SD, standard deviation; GLP-1RA, glucagon-like peptide 1 receptor agonist; LIS, low-income subsidy; MAOI, monoamine oxidase inhibitor; SGLT2i, sodium/glucose cotransporter 2 inhibitor; SSRI, selective serotonin reuptake inhibitor; Unk/unspc, CKD stage unknown or unspecified.